{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:03:18Z","timestamp":1785855798616,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003522"],"award-info":[{"award-number":["82003522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC0548"],"award-info":[{"award-number":["2023NSFSC0548"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.breast.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T05:35:38Z","timestamp":1690176938000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Differences between the efficacy of HER2(2+)\/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-2908","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-8261","authenticated-orcid":false,"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2023.07.008_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.breast.2023.07.008_bib2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2023.07.008_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.breast.2023.07.008_bib4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10087","key":"10.1016\/j.breast.2023.07.008_bib5","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2023.07.008_bib6","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1016\/j.breast.2023.07.008_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.breast.2023.07.008_bib8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.008_bib9","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.breast.2023.07.008_bib10","doi-asserted-by":"crossref","first-page":"e1359","DOI":"10.1097\/MD.0000000000001359","article-title":"Interrelationships between Ki67, HER2\/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study","volume":"94","author":"Shokouh","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.breast.2023.07.008_bib11","article-title":"Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.breast.2023.07.008_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.surg.2014.01.009","article-title":"Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?","volume":"155","author":"Sueta","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.breast.2023.07.008_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2023.07.008_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2023.07.008_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ctrv.2014.05.001","article-title":"Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials[J]","volume":"40","author":"Bria","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.breast.2023.07.008_bib16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ajcp\/aqw045","article-title":"Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer","volume":"145","author":"Li","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.breast.2023.07.008_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"issue":"33","key":"10.1016\/j.breast.2023.07.008_bib18","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.2217\/fon-2022-0663","article-title":"Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study","volume":"18","author":"P\u00e9rez-Garc\u00eda","year":"2022","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.07.008_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:11Z","timestamp":1760777231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623005313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":19,"alternative-id":["S0960977623005313"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.008","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences between the efficacy of HER2(2+)\/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}